Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498631 | 0.90 | CA1 (0.42) | MAPTLMNAATMSMN1; SMN2MAOB | |
| SCHEMBL498788 | 0.89 | MAOB (0.43) | MAPTLMNAHPGDATMSMN1; SMN2 | |
| SCHEMBL15361865 | 0.88 | CYP1A1 (0.49) | MAOBCXCL12CYP1B1 | |
| SCHEMBL29381917 | 0.88 | CYP1A1 (0.49) | MAOBCXCL12CYP1B1 | |
| SCHEMBL498873 | 0.88 | PPARG (0.46) | MAPTLMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL29379677 | 0.88 | PPARG (0.46) | MAPTLMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL29214716 | 0.87 | CYP1A1 (0.37) | MAPTLMNASMN1; SMN2MAOBMAPK1 | |
| SCHEMBL15361844 | 0.87 | CYP1A1 (0.37) | MAPTLMNASMN1; SMN2MAOBMAPK1 | |
| SCHEMBL498833 | 0.86 | MAPT (0.44) | MAPTLMNAHPGDATMSMN1; SMN2 | |
| SCHEMBL498820 | 0.86 | ABCG2 (0.41) | MAPTLMNAHPGDL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | claimed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | claimed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | claimed |
| US-7632870-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2009-12-15 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| EP-1525177-B1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-27 | — | — | EP | claimed |
| EP-1519908-B1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-13 | — | — | EP | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7385082-B2 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | MAPT 133/4885LMNA 1551/4885HPGD 848/4885 |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | MAPT 3226/4885LMNA 1079/4885HPGD 153/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | MAPT 3226/4885LMNA 1079/4885HPGD 153/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | MAPT 3226/4885LMNA 1079/4885HPGD 153/4885 |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | MAPT 3226/4885LMNA 1079/4885HPGD 153/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | MAPT 1275/4885LMNA 205/4885HPGD 402/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | MAPT 3226/4885LMNA 1079/4885HPGD 153/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | MAPT 1087/4885LMNA 1823/4885HPGD 252/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | MAPT 1298/4885LMNA 100/4885HPGD 458/4885 |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | DPEP1, PKD1, ENPP1 | MAPT 4452/4885LMNA 894/4885HPGD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.